Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the acceptance of data from its Phase 2 trial, RELIEF-PHN-1, for investigational drug LX9211 in treating postherpetic neuralgia (PHN) at the AAN Annual Meeting in Boston.
The trial results will be presented on April 24, 2023. Previous data from December 2022 indicated LX9211's potential as an effective non-opioid treatment for neuropathic pain, following positive results from another trial, RELIEF-DPN-1, demonstrating significant pain reduction.
LX9211 targets neuropathic pain via AAK1 inhibition and has Fast Track designation from the FDA for diabetic peripheral neuropathic pain. Overall, the company aims to develop innovative medicines to transform patient care.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. Key executives, including CEO Lonnel Coats, CFO Jeffrey L. Wade, and CMO Craig Granowitz, will engage in a moderated discussion on April 19th at 10:15 AM ET.
The event will be streamed live, and the recording will be accessible for two weeks post-event on the company’s website. Lexicon is focused on developing innovative medicines through its Genome5000™ program, which has identified over 100 protein targets for various diseases.
With a commitment to transforming lives, Lexicon has one marketed medicine and is actively developing candidates for conditions like heart failure and diabetes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced new analyses from the SOLOIST-WHF Phase 3 study of sotagliflozin, revealing a statistically significant reduction in risk for cardiovascular events by Day 27 for patients with worsening heart failure. This analysis demonstrated the first day post-randomization where the hazard ratio for the primary outcome was significant (p<0.05). The study included 1,222 patients with type 2 diabetes recently hospitalized for worsening heart failure and showed a 33% reduction in composite cardiovascular outcomes.
Lexicon Pharmaceuticals has launched a new disease awareness campaign named “INTO THE DARK” to address the critical period following heart failure (HF) hospitalization. Focusing on the first 30 days post-discharge, the campaign highlights that nearly 25% of HF patients are readmitted within this timeframe, facing a 7% mortality rate. Each rehospitalization costs the healthcare system about $15,000-26,000. The initiative was unveiled at the American College of Cardiology’s 72nd Annual Scientific Session in New Orleans, emphasizing the urgent need for increased awareness and education among healthcare professionals to reduce rehospitalizations.
Lexicon Pharmaceuticals (NASDAQ: LXRX) is set for a May 2023 PDUFA date for their NDA for sotagliflozin in heart failure treatment, confirmed during a recent FDA meeting. The company highlighted positive outcomes from their SOLOIST-WHF trial, showing a 50% reduction in readmission rates for heart failure post-discharge. For LX9211, the Phase 2 studies in diabetic peripheral neuropathic pain and postherpetic neuralgia showed promising results, though the latter's primary endpoint wasn't statistically significant. Financially, Q4 2022 recorded a net loss of $30.5 million but has $138.4 million in cash, a notable increase from $86.7 million in Q4 2021.